Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Fig. 2

Number of study months eptinezumab-treated patients maintained same monthly migraine response achieved in Weeks 1–12. Percentage of ≥ 75% migraine responders in (A) PROMISE-1 and (B) PROMISE-2 and percentage of ≥ 50–< 75% migraine responders in (C) PROMISE-1 and (D) PROMISE-2. CM, chronic migraine; EM, episodic migraine; Epti, eptinezumab

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us